This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zipsor

Depomed, Inc.

Drug Names(s): diclofenac potassium

Description: Zipsor is a proprietary immediate release liquid-filled soft gelatin capsule containing 25 mg of diclofenac potassium for oral administration.

Deal Structure: Xanodyne and aaiPharma
In July 2005, Xanodyne Pharmaceuticals announced that the Bankruptcy Court for the District of Delaware approved its bid to acquire the pharmaceutical assets (which are primarily in pain management) of aaiPharma.

Xanodyne and Ferring
In April 2010, Ferring and Xanodyne signed a co-promotion agreement for Zipsor. Under the agreement, Ferring's orthopaedic sales force will promote Zipsor to certain orthopaedic surgeons, rheumatologists, sports medicine physicians and physiatrists in the United States. Ferring will receive a royalty on Zipsor sales generated by a pre-defined target prescriber base.

Depomed and Xanodyne
In June 2012, Depomed acquired all rights to Zipsor (diclofenac potassium) Liquid Filled Capsules from Xanodyne. Depomed acquired the product in return for $25.9 million of cash and potential milestone payments based on sales of Zipsor and assumption of certain liabilities.

Partners: Ferring BV


Zipsor News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug